Li Dean Y, a director at Recursion Pharmaceuticals, Inc., recently reported the acquisition of 3,378 shares of Class A common stock. This transaction, executed on October 1, 2026, is part of the company's Outside Director Compensation Policy. The move underscores the alignment of director interests with those of shareholders, a crucial aspect in the competitive landscape of the biological products industry.
Background
Recursion Pharmaceuticals, Inc. operates in the biological products sector, specifically focusing on innovative therapies. The company, incorporated in Delaware, is listed under the Central Index Key 0001601830. Its business address is located at 41 S. Rio Grande Street, Salt Lake City, UT, 84101. The firm has been active in filing various reports, including recent Form 4 submissions, indicating ongoing transactions by its directors.
What the Filing Says
According to the latest filing (accession number 0001601830-26-000115), Li Dean Y acquired 3,378 shares at no cost, with a total of 1,476,707 shares owned following this transaction. The filing notes, "The shares were issued pursuant to the Issuer's Outside Director Compensation Policy." This highlights the company's strategy to compensate directors through equity, fostering a vested interest in the company's performance.
Impact
This transaction may affect various stakeholders, including shareholders and potential investors, as it reflects the confidence of directors in the company's direction. Li Dean Y's significant shareholding indicates a strong belief in Recursion Pharmaceuticals' future growth and stability.
What's Next
The filing does not say what happens next.